CLINICAL_TRIALS trial_result · 2017-06-14

Clinical Trial Update: Trisenox® in Women With Metastatic Endometrial Cancer [Phase 2]

Phase 2 trial of Trisenox (arsenic trioxide) in women with metastatic endometrial cancer was terminated; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Endometrial Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2017-06-14